KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Prepaid Assets (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Prepaid Assets data on record, last reported at $243.7 million in Q3 2025.

  • For Q3 2025, Prepaid Assets rose 32.33% year-over-year to $243.7 million; the TTM value through Sep 2025 reached $243.7 million, up 32.33%, while the annual FY2024 figure was $217.9 million, 6.09% up from the prior year.
  • Prepaid Assets reached $243.7 million in Q3 2025 per IONS's latest filing, up from $226.1 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $243.7 million in Q3 2025 and bottomed at $123.8 million in Q1 2021.
  • Average Prepaid Assets over 5 years is $175.1 million, with a median of $174.1 million recorded in 2024.
  • Peak YoY movement for Prepaid Assets: decreased 6.81% in 2021, then surged 32.33% in 2025.
  • A 5-year view of Prepaid Assets shows it stood at $143.4 million in 2021, then increased by 17.35% to $168.3 million in 2022, then grew by 22.1% to $205.4 million in 2023, then rose by 6.09% to $217.9 million in 2024, then increased by 11.84% to $243.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Prepaid Assets were $243.7 million in Q3 2025, $226.1 million in Q2 2025, and $222.6 million in Q1 2025.